Cargando…
Efficacy and Safety of Adalimumab in Moderately to Severely Active Cases of Ulcerative Colitis: A Meta-Analysis of Published Placebo-Controlled Trials
BACKGROUND/AIMS: To evaluate the efficacy and safety of adalimumab (ADA) in moderately to severely active ulcerative colitis (UC) patients who are unresponsive to traditional therapy. METHODS: Electronic databases, including the PubMed, Embase, and Cochrane databases, were searched to April 20, 2014...
Autores principales: | Zhang, Zong Mei, Li, Wei, Jiang, Xue Liang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Editorial Office of Gut and Liver
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4780457/ https://www.ncbi.nlm.nih.gov/pubmed/26780088 http://dx.doi.org/10.5009/gnl15042 |
Ejemplares similares
-
Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis
por: Suzuki, Yasuo, et al.
Publicado: (2013) -
Efficacy and safety of the adalimumab biosimilar Exemptia as induction therapy in moderate-to-severe ulcerative colitis
por: Midha, Vandana, et al.
Publicado: (2018) -
Developments in the treatment of moderate to severe ulcerative colitis: focus on adalimumab
por: Freeman, Hugh J
Publicado: (2013) -
Understanding the Role of Adalimumab in the Treatment of Moderately to Severely Active Ulcerative Colitis
por: Kim, Jae Hyun, et al.
Publicado: (2016) -
Efficacy of infliximab and adalimumab therapy in very early onset, severe ulcerative colitis
por: Rohani, Pejman, et al.
Publicado: (2021)